Blinatumomab in B-ALL: BiTE Structure, Mechanism, Resistance & Trials
Blinatumomab is a first-in-class BiTE immunotherapy for B-ALL. Explore its molecular structure, T-cell redirection mechanism, resistance pathways, and clinical trials. Read more
Tag: relapsed B-ALL